



TIME	TOPICS
12:30 /14:00	Welcome Lunch
14:05 / 14:15	Opening of the Seminar
SESSION 1	REGULATION, VALIDATIONS, EDUCATION and OUTREACH
14:15 / 14:35	Regulation and Alternative Methods to Animal Testing : Current status and perspectives
14:35 / 14:55	Phototoxicity : Recent advancements of a 3D model based assay
14:55 / 15:15	Genotoxicity on 3D models : New Developments on the EpiSkin model
15:15 / 15h35	Skin Sensitization with 3D models : myth or reality ? The SENS-IS case study
15:35 / 15:55	Coffee break
15:55 / 16:15	BRAZIL is ON : Animal Testing Ban and available OECD TG in Brazil
16:15 / 16:35	Medical Devices : ISO moves to Alternatives
SESSION 2	BEYOND VALIDATION - Part I
16:35/16:55	Eyes wide open on success story: from TG 492 to EYEIRR-IS Assay.
16:55 / 17:35	HCE : A toolbox for Cosmetic and Pharma Research
17:35 / 18:00	Round Table with the speakers
18:00	End of Day One
18:00 / 22:00	Get Together / Let's Enjoy Lyon / Social Event

TIME	TOPICS
08:30 /09:00	Welcome Coffee
SESSION 2	BEYOND VALIDATION - Part II
09:00 / 09:20	EPISKIN RHE Skin Inflamation Assay : A powerful tool to prevent and sooth skin inflamation
09:20 / 09:40	Histology on 3D models : THE endpoint of interest ?
09:40 / 10:00	Skin and associated MicroBiome
10:00 / 10:20	Sensitization assessment using SkinEthic RHE: the SENSIL-18 test, a wide applicability domain assay for topically applied products
10:20 / 11:00	Coffee break
SESSION 3	INNOVATION
11:00/11:20	Long term culture for repeated dose assay : Are 3D models relevant ?
11:20 / 11:40	RHE-LC, reconstructed epidermis including Langerhans cells, a useful tool for skin immunity study and evaluation.
11:0 / 12:20	Recent advances in skin biology
12:20 / 12:40	Tissue Bio Printing: 3D model 2.0?
12:40 / 13:00	Round Table with the speakers
12:40 / 13:00 13:00	Round Table with the speakers End of Seminar / Wrap Up
	End of Seminar / Wrap Up

2nd EPISKIN INTERNATIONAL SEMINAR – LYON, FRANCE

on Safety and Efficacy applications of 3D human tissue models as alternatives to Animal Testing